- Home
- ZENV vs SAVA Comparison
ZENV vs SAVA Comparison
Compare ZENV & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- SAVA
- Stock Information
- Founded
- ZENV 2005
- SAVA 1998
- Country
- ZENV Brazil
- SAVA United States
- Employees
- ZENV N/A
- SAVA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- SAVA Health Care
- Exchange
- ZENV Nasdaq
- SAVA Nasdaq
- Market Cap
- ZENV 65.5M
- SAVA 70.5M
- IPO Year
- ZENV 2021
- SAVA N/A
- Fundamental
- Price
- ZENV $1.45
- SAVA $2.05
- Analyst Decision
- ZENV
- SAVA Buy
- Analyst Count
- ZENV 0
- SAVA 3
- Target Price
- ZENV N/A
- SAVA $54.50
- AVG Volume (30 Days)
- ZENV 100.5K
- SAVA 1.2M
- Earning Date
- ZENV 07-14-2025
- SAVA 08-07-2025
- Dividend Yield
- ZENV N/A
- SAVA N/A
- EPS Growth
- ZENV N/A
- SAVA N/A
- EPS
- ZENV N/A
- SAVA N/A
- Revenue
- ZENV $155,164,999.00
- SAVA N/A
- Revenue This Year
- ZENV $8.58
- SAVA N/A
- Revenue Next Year
- ZENV $8.83
- SAVA N/A
- P/E Ratio
- ZENV N/A
- SAVA N/A
- Revenue Growth
- ZENV 18.83
- SAVA N/A
- 52 Week Low
- ZENV $1.02
- SAVA $1.15
- 52 Week High
- ZENV $3.30
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- ZENV 52.70
- SAVA 51.70
- Support Level
- ZENV $1.21
- SAVA $2.02
- Resistance Level
- ZENV $1.57
- SAVA $2.25
- Average True Range (ATR)
- ZENV 0.10
- SAVA 0.11
- MACD
- ZENV 0.03
- SAVA -0.02
- Stochastic Oscillator
- ZENV 67.57
- SAVA 29.03
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.